Company Overview and News
Fixed Maturity Plans or FMPs are back in the game in a big way with new fund offers from 10 mutual fund houses already on, and many more set for launch in the days to come.
After a fantastic year for Indian equity markets, domestic mutual fund industry experts are hoping for another blockbuster year in 2018.
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.
Vishal Sikka, resigned from his post of MD & CEO of Infosys effective today. The stock was the top loser on both S&P BSE Sensex and Nifty.
MUMBAI (Reuters) - The Reserve Bank of India (RBI) will likely have to drain up to $22 billion in excess liquidity from the financial system as surging foreign investments forces the central bank to absorb the dollar inflows and sell rupees to cap gains in the local currency.
Trading Members of the Exchange are hereby informed that, Kotak Mahindra Asset Management Ltd. has informed and requested that trading in units of the following schemes are not available for trading on the Exchange pursuant to the record date of June 16,2017 fixed for the purpose of determining unit holders.
Markets regulator Sebi has asked several mutual fund houses to explain the rise in fund inflows from promoter group entities and associates to their overall assets under management.
Kotak Mahindra Mutual Fund has revised the features of Kotak Multi Asset Allocation Fund, with effect from Apr 12.
Four of the country’s biggest funds chose to abstain from voting on Maruti Suzuki’s contentious related-party transaction with its Japanese parent in December 2015, voting disclosures by the fund houses show. Similarly, in the case of Vedanta-Cairn merger, four of the top five mutual fund firms voted for it despite concerns around the use of cash on Cairn’s books.
Trading Members of the Exchange are hereby informed that, Kotak Mahindra Asset Management Company Ltd. has now informed and requested the Exchange to ensure that the units of the below mentioned scheme are not available for trading on the Exchange pursuant to Record date of 20th February 2017 fixed for maturity of the said Mutual Fund Scheme.
Trading Members of the Exchange are hereby informed that, Kotak Mahindra Asset Management Company Ltd. has now informed and requested the Exchange to ensure that the units of the below mentioned scheme are not available for trading on the Exchange pursuant to Record date of 13th February 2017 fixed for maturity of the said Mutual Fund Scheme.
Demonetisation will dent corporate profits for this quarter and the next, and a recovery is likely only in FY18, says Shibani Sircar Kurian Senior Vice President & Head -Equity Research, Kotak Mahindra Mutual Fund
Re-Listing of units of Kotak FMP Series 131 a scheme under Kotak Mahindra Mutual Fund after rollover
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...